Martin Svaton1, Milada Zemanova2, Petra Zemanova2, Juraj Kultan3, Ondrej Fischer3, Jana Skrickova4, Lenka Jakubikova4, Marketa Cernovska5, Michal Hrnciarik6, Michal Jirousek6, Jana Krejci7, Daniel Krejci7, Ondrej Bilek8, Jiri Blazek9, Karolina Hurdalkova10, Magda Barinova10, Bohuslav Melichar11. 1. Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic svatonm@fnplzen.cz. 2. Department of Oncology, Charles University, First Faculty of Medicine in Prague, Prague, Czech Republic. 3. Department of Respiratory Medicine, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic. 4. Department of Respiratory Diseases and TB, Faculty of Medicine, Masaryk University Brno and University Hospital Brno, Brno, Czech Republic. 5. Department of Respiratory Medicine, First Faculty of Medicine of Charles University, Thomayer Hospital Prague, Prague, Czech Republic. 6. Department of Pneumology, Charles University, Faculty of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic. 7. Department of Pneumology, Charles University, Faculty of Medicine in Prague, Prague, Czech Republic. 8. Department of Comprehensive Oncology, Masaryk Institute of Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 9. Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic. 10. Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 11. Department of Oncology, Palacky University, Faculty of Medicine and Dentistry, Olomouc, Czech Republic.
Abstract
AIM: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. RESULTS: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. CONCLUSION: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment. Copyright
AIM: To investigate potential association between administration of corticosteroids, antibiotics, probiotics, proton pump inhibitors, non-steroidal anti-inflammatory drugs (NSAID), statins and metformin and outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. PATIENTS AND METHODS: A total of 224 patients with advanced NSCLC treated at nine comprehensive cancer centers were analyzed in this national retrospective study. Survival statistics were evaluated using Kaplan-Meier method and Cox analysis. RESULTS: Only corticosteroid use had a significant negative effect on the objective response rate. In the univariate analysis, there was no significant effect of the studied concomitant medications on the efficacy of nivolumab. In a subsequent multifactorial analysis, a possible positive effect of the concomitant use of NSAID at the initiation of nivolumab treatment was revealed. CONCLUSION: The results of the present retrospective exploratory analysis underscore the importance of knowing the exact type of concomitant medication, the route of administration, the dose of medication, and the region of the ongoing study. The present data indicated a significantly higher rate of progression in patients treated with corticosteroids and the possible positive effect of NSAID use at the initiation of nivolumab treatment. Copyright
Authors: Alexandra Drakaki; Preet K Dhillon; Heather Wakelee; Stephen Y Chui; Jinjoo Shim; Matthew Kent; Viraj Degaonkar; Tien Hoang; Virginia McNally; Patricia Luhn; Ralf Gutzmer Journal: Oncoimmunology Date: 2020-10-05 Impact factor: 8.110